Business Wire

Airline Passenger Capacity is Projected to Grow at 47% in 2022

8.12.2021 12:00:00 EET | Business Wire | Press release

Share

Global aviation analytics firm Cirium, has released its second annual Airline Insights Review, which reveals an industry in recovery and poised for a projected 47% growth in capacity (the number of seats flown) in 2022. This steep increase indicates capacity could return to 2015 levels by the end of next year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208005398/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Airlines are poised for a projected 47% growth in capacity (by seats flown) in 2022, as revealed in Cirium's new Airline Insights Review. (Graphic: Business Wire)

Last year, the pandemic and its consequences wiped out 15 years of global passenger capacity growth—based on the total number of seats flown—in a matter of months, reducing 2020 capacity flown to levels last seen in 2005.

Although recovery was varied in 2021, global capacity is forecasted to return to capacity levels seen in 2006 by the end of the year.

Regions with strong domestic markets showed accelerated recovery this year—in particular, in the US and China. In fact, Chinese domestic flights are up 6% compared to pre-pandemic levels in 2019.

Of all the flights tracked January to October 31 worldwide, 78% were domestic flights. International flights experienced a slow recovery with many restrictions in place until Q4 of 2021, and some restrictions still in place, depending on the routes. Indeed, international flights saw a 6% growth in 2021 compared to the same period in 2020.

“The past year has had its challenges as we continued to face fluctuating cases of COVID-19, new variants—most recently Omicron—and varied vaccination programs per country. There is light at the end of the tunnel as we see international travel corridors reopening. However, we will continue to track this momentum as new variants arise and we hope the invaluable analyses in our Airline Insights Report help to navigate what’s to come,” said Jeremy Bowen, CEO of Cirium.

Cirium predicts a year of acceleration in 2022

“Cirium’s experts have analysed 2021 data and formulated forecasts for 2022 and beyond. Near the end of 2022, global capacity will return to 2015 levels, as we see a steep increase in more seats returning to the skies.

“In Cirium’s Airline Insights Report, we have included Seven Things to Look for in 2022 to enable the industry to gain insight into these forecasts and use them to anticipate market developments and make well-informed decisions,” Bowen added.

As more passengers steadily return to the skies, this will mean worldwide domestic traffic (measured in passenger numbers) is predicted to be back to pre-pandemic levels by the end of 2022. International passenger traffic is likely to reach two-thirds of 2019 levels.

Cirium projections show that the global passenger fleet in service will increase to 20,700 by the end of 2022—only a few hundred less than at the end of 2019—pre-pandemic.

The slow recovery of business travel seen so far will change in 2022, with predictions from the industry that there will be a 36% surge in business travel year-over-year. According to Cirium data, business events being tracked online are already increasing for next year.

Conversions of passenger jets to freighters will continue to increase and in 2022, with a potential total of 160 passenger jets converted to freighters—surpassing previous conversion figures.

Aircraft values and lease rates took an unprecedented hit in the past 12 months, however Cirium suggests that they’ve reached the bottom as the values and lease rates for many aircraft types have stabilized and a few are improving. Some aircraft types remain on watch next year, including the Airbus A350 and the Boeing 787.

Cirium anticipates that airlines will increasingly rely on partnerships to carry passengers into partner home markets in 2022. This will mean a shift in airlines flying secondary markets post-pandemic and instead see them taking advantage of their airline partners to fly passengers to secondary cities.

As more flights return to the skies, it’s no surprise that CO2 emissions will increase next year—the CO2 emissions from flights in 2021 were 40% less than pre-pandemic. However, airlines are returning more fuel-efficient fleets to service and sustainability has become front and center in aviation, with many looking at fuel burn and how to reach net zero 2050 targets.

“Cirium anticipates the return to normalcy will usher in more focus on sustainable travel practices, including younger, more fuel-efficient aircraft, and the ability to more closely measure the impact of airline travel on global greenhouse gas emissions,” said Bowen.

To read the full Cirium Airline Insights Review 2021, including the seven predictions of 2022 – click here.

The 2021 Airline Insights Report is Cirium’s collection of expert analyses covering a wide range of topics surrounding airlines at the core and the aviation industry that encircles them. The report covers:

  • Top routes flown and airports in 2021
  • The current state of the global passenger traffic, capacity and fleet
  • Sustainability initiatives in the airline industry
  • Airline startups and new routes flown in 2021
  • Average airfares in key markets
  • Spotlights on APAC and Latin America

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media enquiries:
Rachel Humphries, Cirium at media@cirium.com
Mike Arnot, Julliett Alpha at cirium@juliettalpha.com
Paul Charles/Michael Johnson/Callum McGoldrick, PC Agency at cirium@pc.agency

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye